John W. Kitchens, MD

Anti-VEGF for RVO: The Gold Standard

Videos

I'm sorry, it seems there is no article provided for me to summarize and extract key takeaways from. Could you please provide the text of the article

John W Kitchens, MD, bookends the discussion by highlighting the landscape of branch vein occlusion (BRVO) treatment options. 

Anti-VEGF for RVO: The Gold Standard 

Faricimab for DME: Durability and Patient Outcomes

I'm sorry, but it seems there is no article text provided for me to summarize and extract key takeaways from. Could you please provide the text of the article

Dante J Pieramici, MD, shifts the conversation to diabetic macular edema (DME) and the promising drying and anatomical results from an open-label long-term extension trial. 

Faricimab for DME: Durability and Patient Outcomes 

Faricimab for nAMD: Key Trial Highlights and Case Example

Margaret A Chang, MD, MS, discusses efficacy and safety results of faricimab for neovascular age-related macular degeneration (nAMD) treatments.

Faricimab for nAMD: Key Trial Highlights and Case Example  

Overview of Real-World Outcomes for nAMD, DME, and RVO Patients

Carl D Regillo, MD, FACS, begins the discussion highlighting each disease state and the landscape of treatment.   

John W. Kitchens, MD

Articles